cystic fibrosis

Safety of Monofluoroquinolones in Pediatric Patients

Clinical Microbiology and Antimicrobial Chemotherapy. 2006; 8(4):359-367

Two groups of children on therapy with monofluoroquinolones were enrolled in this open trial: 169 patients with cystic fibrosis (exacerbation period) and 55 patients with aplastic anemia (neutropenic phase); age was from 6 months to 16 years. The aim …

Infections Caused by Nonfermenting Gram-negative Rods: Epidemiological, Microbiological and Clinical Features

Clinical Microbiology and Antimicrobial Chemotherapy. 2005; 7(3):271-285

Nonfermenting gram-negative rods (NGR) are one of the leading nosocomial pathogens. Among them Pseudomonas aeruginosa, Acinetobacter baumannii, Pseudomonas aeruginosa, Acinetobacter spp., Burkholderia spp., Stenotrophomonas spp., and Chryseobacterium …

Quinolones in Childhood and Pregnancy. Is There a Rationale for Their Use?

Clinical Microbiology and Antimicrobial Chemotherapy.2004; 6(4):377-393

The usage of quinolones and fluoroquinolones (FQ) in children and adolescents as well as in pregnant women is considered in this paper. Based on joint toxicity of FQ observed in immature animals this class of antimicrobial agents is officially …